ADMA (ADMA Biologics) Current Accrued Expense: $28.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $9.48
GF Value $18.10
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Current Accrued Expense?

ADMA Biologics ADMA +0.58% 64 Current Accrued Expense is $28.1 Mil as of Jun. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.10 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $28.1 Mil.

ADMA Biologics's quarterly Current Accrued Expense increased from Dec. 2025 ($27.7 Mil) to Mar. 2026 ($28.1 Mil) and increased from Mar. 2026 ($28.1 Mil) to Jun. 2026 ($28.1 Mil).

ADMA Biologics's annual Current Accrued Expense declined from Dec. 2023 ($30.6 Mil) to Dec. 2024 ($28.6 Mil) and declined from Dec. 2024 ($28.6 Mil) to Dec. 2025 ($27.7 Mil).

ADMA Biologics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Current Accrued Expense Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.20 23.19 30.55 28.63 27.68

ADMA Biologics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.71 23.48 27.68 28.09 28.11
ADMA
64GF Score
ADMA Biologics Inc ADMA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $28.1 Mil mean?
ADMA Biologics (ADMA) has a Current Accrued Expense of $28.1 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Current Accrued Expense too high?
ADMA Biologics' current Current Accrued Expense is $28.1 Mil. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Current Accrued Expense compare to ZBIO and PGEN?
ADMA Biologics' Current Accrued Expense of $28.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Current Accrued Expense is $28.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.10, compared to a current price of $9.48 — trading 47.6% below its estimated fair value. The current Current Accrued Expense is $28.1 Mil. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Current Accrued Expense is $28.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $9.48 is trading 47.6% below its estimated GF Value™ of $18.10. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Current Accrued Expense: $28.1 Mil
  • GF Value™: $18.10 vs. price of $9.48 (47.6% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.48
Price
$18.10
GF Value